Oppenheimer Thinks Protara Therapeutics’ Stock is Going to Recover

Oppenheimer analyst Leland Gershell initiated coverage with a Buy rating on Protara Therapeutics (TARAResearch Report) today and set a price target of $43.00. The company’s shares closed last Tuesday at $20.88, close to its 52-week low of $15.86.

According to TipRanks.com, Gershell is a 5-star analyst with an average return of 26.4% and a 54.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Viridian Therapeutics, and CASI Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Protara Therapeutics with a $43.00 average price target.

See today’s analyst top recommended stocks >>

Based on Protara Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $7.97 million. In comparison, last year the company had a GAAP net loss of $2.35 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ArTara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY.